Sintaho Pharmaceutical Ltd was established in the year of 2016 and headquartered in Chongqing China, with a grand vison of being the most trusted partner to pharmaceutical companies worldwide. We have a clear focus on developing and manufacturing highly potent and cytotoxic Active Pharmaceutical Ingredients (APIs) and CDMO services.
*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p><strong>Cabazitaxel Monohydrate</strong> is a third-generation taxane chemotherapy agent produced via semi-synthetic organic synthesis. Its molecular formula is C<sub>45</sub>H<sub>53</sub>NO<sub>12</sub>, and it carries CAS No. <strong>908764-43-2</strong>.</p>
<h3>Application</h3>
<ul>
<li>Oncology: Treatment of metastatic castration-resistant prostate cancer.</li>
<li>Pharmaceutical Manufacturing: Active Pharmaceutical Ingredient (API) for generic drug production.</li>
<li>Clinical Research: Standardized compound for comparative efficacy studies in oncology trials.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly contraindicated for patients with severe neutropenia or hypersensitivity to cabazitaxel. Store in sealed containers at 2°C to 8°C protected from light and moisture to maintain chemical stability.</p>